Myeloablative Total Body Irradiation Plus Fludarabine or Cyclophosphamide as Conditioning for Patients With AML Undergoing Allogeneic HCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Am. J. Hematol 2023 Jan 10;[EPub Ahead of Print], S Giebel, M Labopin, T Schroeder, R Swoboda, J Maertens, JH Bourhis, G Grillo, U Salmenniemi, I Hilgendorf, N Kröger, X Poiré, JJ Cornelissen, M Arat, B Savani, A Spyridonidis, A Nagler, M MohtyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.